Launch of generic Farxiga (Dapagliflozin Propanediol tablets)
The generic formulation of Farxiga, Dapagilflozin Propanediol tablets has been recently release.
DAPAGLIFLOZIN TABLETS are indicated:
- To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
- To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure.
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin Propanediol tablets are manufactured by Prasco Laboratories. It is available in 5mg and 10mg tablets.